How is Orna using RNA to create therapeutics for cancer? Using circular RNA, we’ve developed a platform we call isCAR™ for the in vivo delivery of CARs to immune cells. RNA is transient, but circular ...
New technique for cell or drug delivery, localization of bioelectric materials, and wound healing uses ultrasound to activate printing within the body. Imagine if doctors could precisely print ...
In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a ...
Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...
Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting 100% MRD-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results